Hennion & Walsh Asset Management Inc. Sells 12,885 Shares of Boston Scientific Corporation $BSX

Posted by Brenda Bartman on Aug 11th, 2026

Boston Scientific logo Hennion & Walsh Asset Management Inc. trimmed its position in Boston Scientific Corporation (NYSE:BSX – Free Report) by 12.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 93,021 shares of the medical equipment provider’s stock after selling 12,885 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Boston Scientific were worth $3,970,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BSX. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at $26,000. Sfam LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at $29,000. Finally, Eagle Bay Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter worth $30,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney bought 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 204,322 shares of company stock worth $9,939,221 in the last three months. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Trading Up 2.3%

NYSE BSX opened at $50.42 on Tuesday. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock’s 50 day moving average price is $45.80 and its two-hundred day moving average price is $60.25. The stock has a market capitalization of $73.07 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 1.08 and a beta of 0.56.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the business earned $0.75 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research firms have weighed in on BSX. Jefferies Financial Group reduced their target price on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, June 24th. Mizuho dropped their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a report on Thursday, May 28th. Wells Fargo & Company decreased their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. Finally, Royal Bank Of Canada lowered their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

View Our Latest Stock Report on Boston Scientific

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.